Adagene Inc.
NASDAQ:ADAG · NASDAQ Global Market
-$0.01 today
Vol 0.06M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.8%
avg -25.2%
ROIC
-36.2%
avg -39.4%
ROA
-22.5%
avg -28.8%
Analysis
ROA is currently the strongest return metric at -22.5% versus its period average of -28.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexander Goergen | Vice President & Head of Business Development | — | — | 39 | — | — |
Yan Li | Senior Vice President of Bioinformatics & Information Technology | — | — | 51 | $0.00 | <0.01% |
Guizhong Liu | Senior Vice President of Early Drug Discovery | — | — | 55 | — | — |
Mickael Chane-Du | Chief Strategy Officer | — | — | — | $188,019.00 | 0.50% |
Qinghai Zhao | Chief Manufacturing Officer | — | — | 65 | $0.00 | <0.01% |
Chunfang Gu | Executive Director of Finance | — | — | — | $0.00 | <0.01% |
Ling Zhou | Executive Director & Head of Human Resources | — | — | — | $9,375.00 | 0.02% |
Xiaohong She | Senior Vice President & Head of Clinical Operations | — | — | 59 | — | — |
Man Kin Tam | Chief Financial Officer & Director | — | — | 49 | $116,583.00 | 0.31% |
Peter Luo | Co- Founder, Chairman, Chief Executive Officer and President of R&D | — | — | 60 | $168,750.00 | 0.45% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +168.5% | +9.9% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +168.5% over three years. Forward estimates point to Revenue at +9.9% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Nutriband Inc.
NTRB
$41.21M
Lite Strategy, Inc.
LITS
$25.22M
CervoMed Inc.
CRVO
$22.68M
Who manages ADAG?
Adagene Inc. (ADAG) lists 10 active executives. The top listed executive is Alexander Goergen, Vice President & Head of Business Development.
Are ADAG insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.